Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CDER Free Speech Response Complicated By Family Ties

This article was originally published in RPM Report

Executive Summary

It’s hard enough for FDA to try to chart its course on promotional claims in the face of shifting opinions in the courts. Now, the CDER management team has to deal with a change in leadership of one of the key internal groups monitoring the issue.

You may also be interested in...



FDA Taps NIH Veteran Corrigan-Curay To Lead Medical Policy Office

Jacqueline Corrigan-Curay joins from the National Heart, Lung and Blood Institute, where she worked on clinical trial initiatives and served as an NIH representative on FDA’s Drug Safety Oversight Board.

The Evolving Door? What Having A ‘Big Data’ Commissioner Might Mean For US FDA

Robert Califf’s nomination to return as FDA commissioner will raise protests about a ‘revolving door’ pathway between industry and agency. But, in this case, it may be more apt to talk about how Califf’s time outside FDA led to evolving views on the role of big data in drug regulation.

AAV Vector Consortia Address Quality Assays, Endpoints

Two outside groups aim to help CBER on gene therapy questions from ‘N of one’ to markers for hemophilia.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS079784

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel